Ignite Creation Date:
2024-05-06 @ 8:40 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02795325
Status:
TERMINATED
Last Update Posted:
2024-07-11
First Post:
2016-05-18
Brief Title:
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 PH1
Sponsor:
Dicerna Pharmaceuticals Inc a Novo Nordisk company
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 PH1
Status:
TERMINATED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 PH1 to determine the safety tolerability pharmacokinetic PK and pharmacodynamics PD effects of DCR-PH1 administered via-intravenous infusion IV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None